17,261 trials
Urticaria · Chronic Spontaneous Urticaria · Chronic Idiopathic Urticaria
Primary: Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Week 12 — -17.90; -17.25; -19.83; -23.91 scores on a scale — p=0.8298
Psoriasis Vulgaris · Topical Administration
Primary: Investigator's Static Global Assessment Scale (ISGA) Scores — 1.46; 2.02; 2.57; 2.60 Score
Mild Cognitive Impairment
Primary: Change in Neurocognitive Performance — 0.146; 0.103 Z-score
Dementia With Lewy Bodies
Primary: Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs) — 42; 40; 37; 14 participants
Cholera
Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003
Stargardt's Macular Dystrophy
Primary: Mean Rate of Change in the Area of Ellipsoid Zone Defect From Baseline Through Month 18 — 0.6383; 0.6644 mm^2/18 months — p=0.8669
Cystic Fibrosis
Primary: Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1 — 62.4; 136; 338 nanograms per milliliter (ng/mL)
Bronchopulmonary Dysplasia
Primary: Safety as Determined by Adverse Event Experienced by Participants — 71; 83; 53; 60 Events
PTSD
Primary: Change in Post Traumatic Stress Disorder Symptom Severity - Clinician Rated — -10.1; -12 units on a scale
Post-Surgical Hypoparathyroidism
Primary: Percent Change in Fractional Excretion of Calcium (FECa) — -39 percentage of change
Adult Grade III Lymphomatoid Granulomatosis · B-cell Chronic Lymphocytic Leukemia · Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Primary: Dose-limiting Toxicity (Phase I) — 0; 0; 2 Participants
Anxiety
Primary: Number of Participants Who Completed Patient-Reported Outcomes (PROs) Questionnaires — 61; 61; 61; 61 Participants
Adult T-cell Leukemia-Lymphoma · ATLL
Primary: Number of Participants Achieving Complete Molecular Response in Blood Compartment (CMR) — 3 Participants
Acute Kidney Injury
Primary: Area Under the Curve (AUC) of Urinary Kidney Injury Biomarker Kidney Injury Molecule-1 (KIM-1) Above Baseline Within 24 Hours Postoperatively — 51.4; 52.3 ng*h/mL
Influenza, Human
Primary: Part 1 YA: Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer — 12.40; 54.78; 83.98; 98.65 Titers